Cellect biotechnology co., ltd. was incorporated as a private company under the name Montiger ltd. by the law of the state of Israel on 4 August 1986. Between 1986 and 2013, they underwent several name changes, most recently on Aug. 28, 2013, when they changed their current name from T.R.F. Capital Ltd. They are an emerging biotechnology company that has developed a novel technology platform called Cellect to functionally select stem cells in order to improve the safety and effectiveness of stem cell therapies in regenerative medicine. Their goal is to become the standard enabling technology for companies to develop stem cell therapies, physicians practicing regenerative medicine, and the enrichment of stem cell populations by researchers and academics engaged in stem cell research.
Market Cap:1.1M; Shares Outstanding:448.2K; Short Interest: /; Q2 2019(6/30/19): Cash 7.8M. Loss 0.23M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 11，no change
Shares hold: 142.6k shares. no change
shares% hold: 6.36%，no change